463 related articles for article (PubMed ID: 17324607)
1. Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system.
Zwirner NW; Fuertes MB; Girart MV; Domaica CI; Rossi LE
Cytokine Growth Factor Rev; 2007; 18(1-2):159-70. PubMed ID: 17324607
[TBL] [Abstract][Full Text] [Related]
2. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
3. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
6. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.
Jinushi M; Takehara T; Tatsumi T; Hiramatsu N; Sakamori R; Yamaguchi S; Hayashi N
J Hepatol; 2005 Dec; 43(6):1013-20. PubMed ID: 16168521
[TBL] [Abstract][Full Text] [Related]
7. Exosomes and the MICA-NKG2D system in cancer.
Clayton A; Tabi Z
Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
[TBL] [Abstract][Full Text] [Related]
8. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
[TBL] [Abstract][Full Text] [Related]
10. Activation of natural killer cells: underlying molecular mechanisms revealed.
Backström E; Kristensson K; Ljunggren HG
Scand J Immunol; 2004; 60(1-2):14-22. PubMed ID: 15238069
[TBL] [Abstract][Full Text] [Related]
11. MICA/NKG2D-mediated immunogene therapy of experimental gliomas.
Friese MA; Platten M; Lutz SZ; Naumann U; Aulwurm S; Bischof F; Bühring HJ; Dichgans J; Rammensee HG; Steinle A; Weller M
Cancer Res; 2003 Dec; 63(24):8996-9006. PubMed ID: 14695218
[TBL] [Abstract][Full Text] [Related]
12. The role of the NKG2D receptor for tumor immunity.
Coudert JD; Held W
Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
[TBL] [Abstract][Full Text] [Related]
13. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
[TBL] [Abstract][Full Text] [Related]
14. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
Zhang C; Zhang J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
[TBL] [Abstract][Full Text] [Related]
15. NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y; Smyth MJ
Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
[TBL] [Abstract][Full Text] [Related]
16. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
18. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
19. Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Kim JY; Bae JH; Lee SH; Lee EY; Chung BS; Kim SH; Kang CD
J Immunother; 2008 Jun; 31(5):475-86. PubMed ID: 18463537
[TBL] [Abstract][Full Text] [Related]
20. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
Guo KY; Mei JZ; Yao KT
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):247-9. PubMed ID: 17425963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]